Showing results (1101-1110 of 1,142) with videos related to

Sort By:
Pageof 115
Nature Cell Biology|May 20, 2020
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistanceMingjun Bi, Zhao Zhang, Yi-Zhou Jiang, et al.
Breast Cancer Research and Treatment|May 17, 2008
Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relativesA-Yong Cao, Juan Huang, Zhen Hu, et al.
Molecular Cancer|March 26, 2022
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trialSong-Yang Wu, Ying Xu, Li Chen, et al.
Cell Reports|March 2, 2022
Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancerTian-Qi Gong, Yi-Zhou Jiang, Chen Shao, et al.
Cell Research|January 10, 2023
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondriaXiao-Qing Xie, Yi Yang, Qiang Wang, et al.
Breast Cancer Research and Treatment|May 1, 2008
The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relativesA-Yong Cao, Juan Huang, Zhen Hu, et al.
BMJ (Clinical Research Ed.)|December 23, 2025
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trialYin Liu, Yue Gong, Xiu-Zhi Zhu, et al.
ACS Chemical Neuroscience|December 30, 2016
The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic ActivitiesWei Li, Jian-Dong Long, Yuan-Yuan Qian, et al.
Nature Genetics|September 28, 2023
Molecular classification of hormone receptor-positive HER2-negative breast cancerXi Jin, Yi-Fan Zhou, Ding Ma, et al.
Cell Research|March 27, 2023
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trialYin Liu, Xiu-Zhi Zhu, Yi Xiao, et al.
Pageof 115